Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
108.2 USD | +2.07% | +2.94% | +7.33% |
Apr. 17 | AdaptHealth Names Suzanne Foster CEO | DJ |
Apr. 02 | Cardinal Health Announces Location of Pharmaceutical Distribution Center for Over-The-Counter Products | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.11 for the 2024 fiscal year.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.33% | 25.78B | C+ | ||
+13.36% | 68.18B | C+ | ||
+6.34% | 7.99B | B | ||
-2.79% | 7.88B | C | ||
-24.02% | 7.62B | B- | ||
+21.83% | 4.45B | B+ | ||
-2.28% | 3.89B | B- | ||
-3.51% | 3.82B | B | ||
+25.02% | 3.69B | C+ | ||
+3.28% | 3.24B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CAH Stock
- Ratings Cardinal Health, Inc.